CHICAGO, Dec. 23, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for dalbavancin. Durata is seeking approval for the marketing and sale of dalbavancin for the treatment of patients with complicated skin and soft tissue infections (cSSTI) caused by susceptible Gram-positive microorganisms, including Staphylococcus aureus (including methicillin-resistant strains) and Streptococcus pyogenes, as well as certain other streptococcal species. The start of the review procedure begins December 26, 2013. The Company anticipates a decision in 1H2015.
Help employers find you! Check out all the jobs and post your resume.